|
|
|
|
| LEADER |
02441nam a2200313 u 4500 |
| 001 |
EB002001444 |
| 003 |
EBX01000000000000001164345 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 130 |
0 |
|
|a Crohn's disease (National Clinical Guideline Centre for Acute and Chronic Conditions (Great Britain))
|
| 245 |
0 |
0 |
|a Crohn's disease
|h Elektronische Ressource
|b management in adults, children, and young people
|c National Clinical Guideline Centre ; commissioned by the National Institute for Health and Care Excellence
|
| 260 |
|
|
|a London
|b Published by the National Clinical Guideline Centre at The Royal College of Physicians
|c 10 October 2012, 2012
|
| 300 |
|
|
|a 1 PDF file (398 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Comparative Effectiveness Research
|
| 653 |
|
|
|a Off-Label Use
|
| 653 |
|
|
|a Crohn Disease / drug therapy
|
| 710 |
2 |
|
|a National Clinical Guideline Centre for Acute and Chronic Conditions (Great Britain)
|
| 710 |
2 |
|
|a Royal College of Physicians of London
|
| 710 |
2 |
|
|a National Institute for Health and Care Excellence (Great Britain)
|
| 740 |
0 |
2 |
|a Crohn's disease (National Institute for Health and Care Excellence (Great Britain))
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Clinical guideline
|
| 500 |
|
|
|a Title from PDF title page
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK247969
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a This guideline intends to show the place of both new and established treatments in the wider care pathway for Crohn's disease. This will be useful for clinicians and people with Crohn's disease because new drugs have been licensed for Crohn's disease in the last decade. The guideline also deals with those medications which are unlicensed for treatment of the condition, but which have been used in this way (off-label) for many years and their role is recognised in other NICE documents as well as the British National Formulary. They include azathioprine, mercaptopurine and methotrexate. The guideline aims to help improve the care offered to people with Crohn's disease and provide information about the clinical and cost effectiveness of potential care pathways. Management of Crohn's disease in specific populations (for example, in pregnancy) may require special consideration
|